Nanoengineering Gone Viral: Plant Virus-based Therapeutics


Nanoengineering Gone Viral: Plant Virus-based Therapeutics

Nicole F. Steinmetz, University of California-San Diego

12:45 p.m.–2:00 p.m., May 18, 2021

Contact ND CBE for Zoom link

Nanoscale engineering is revolutionizing the way we detect, prevent and treat diseases. Viruses are playing a special role in these developments because they can function as prefabricated nanoparticles. We utilize and build-upon the high-precision assemblies of the viral capsids and utilize them as platform technologies, engineered and repurposed for a desired function. More specifically, we turned toward plant viruses as a platform nanotechnology.

Dr. Steinmetz
Dr. Steinmetz

We have developed a library of plant virus-based nanoparticles and through structure-function studies. We are beginning to understand how to tailor these materials appropriately for applications targeting human, veterinary, and plant health.

Through chemical biology, we have developed virus-based delivery systems carrying medically relevant cargo enabling tissue-specific imaging and treatment. A particularly exciting avenue is the development of plant virus-like particle platforms for cancer immunotherapy. The idea pursued is an ‘in situ vaccination’ to stimulate local and systemic anti-tumor immune responses to treat established disease, and most importantly to induce immune memory to protect patients from outgrowth of metastasis and recurrence of the disease. Another avenue is the repurposing of plant viruses to enable plant health; we employ principles of nanomedicine to target pesticides residing deep in the soil, therefore, challenging to reach using contemporary pesticides.

Dr. Steinmetz of the University of California, San Diego will highlight engineering design principles employed to synthesize the next-generation nanotherapeutics using plant virus-based platform technologies, and I will discuss the evaluation of such in preclinical mouse models and canine patients as well as in the agricultural arena.

Dr. Steinmetz is a Professor of NanoEngineering at the University of California, San Diego. She is the founding Director of the Center for Nano-ImmunoEngineering (nanoIE) and serves on the Leadership Team for a UC San Diego Materials Research Science and Engineering Center (MRSEC). She started her independent career at Case Western Reserve University School of Medicine in the Department of Biomedical Engineering (in 2010), where she was promoted through the ranks of Assistant, Associate, and Full Professor. Dr. Steinmetz trained at The Scripps Research Institute, La Jolla, CA where she was an NIH K99/R00 awardee and AHA post-doctoral fellow (2007-2010); she obtained her Ph.D. in Bionanotechnology from the University of East Anglia where she prepared her dissertation as a Marie Curie Early Stage Training Fellow at the John Innes Centre, Norwich, UK (2004-2007). Her early training was at the RWTH-Aachen University in Germany. Dr. Steinmetz’s research program focuses on the engineering of plant virus-based nanomaterials targeting human and plant health applications, such as therapeutic delivery, molecular imaging, and next-generation vaccines and immunotherapies. Dr. Steinmetz has authored more than 190 journal articles (H index 50) and is a standing member of the NIH Nanotechnology study section. She serves on the Editorial Board of Wiley Interdisciplinary Reviews (WIREs) on Nanomedicine and Nanobiotechnology as well as the Advisory Editorial Board for the ACS Nano, Molecular Pharmaceutics, Journal of Materials Chemistry B, and Materials Advances. Dr. Steinmetz is a Fellow of the Royal Society of Chemistry (FRSC, since 2018) and a Fellow at the American Institute of Medical and Biological Engineering. She has won many awards, including an American Cancer Society (ACS) Research Scholar Award (2016), and a Young Innovator of Cellular and Molecular Bioengineering Award from the Biomedical Engineering Society (2015). Dr. Steinmetz’s research program is supported through grants from NIH, NSF, NIFA, CDMRP as well as ACS, Susan G. Komen, and AHA, amongst other agencies. Over the past 10 years, Dr. Steinmetz has been awarded grants as PI and Co-PI totaling $41+ million.

Contact the ND CBE Department for Zoom link.